Information  X 
Enter a valid email address

Byotrol PLC (BYOT)

  Print          Annual reports

Wednesday 08 December, 2021

Byotrol PLC

Interim Results and Investor Presentation

RNS Number : 8990U
Byotrol PLC
08 December 2021
 

 

 

 

 

 

8 December 2021

Byotrol Plc

 

("Byotrol" or the "Group")

 

Interim results and Notice of Investor Presentation

 

 

Byotrol Plc (AIM: BYOT), the specialist infection prevention and control company, is pleased to announce today its unaudited interim results for the six months ended 30 September 2021.

 

Highlights

 

Performance in the first six months showed substantial and ongoing improvements compared to our performance pre-Covid, but was below management expectations for the period, matching the experience of other companies in our markets and reflecting slower than expected and overstocked markets post the peak of the pandemic demand.

 

· Sales £3.2m (versus an exceptional Covid-driven £6.7m in 6m to 30 September 2020, and £2.1m * in the 6 months to 30 September 2019)

· Gross profit £1.66m (v.£2.91m and £0.91m respectively)

· Adjusted EBITDA ** £0.17m (versus £1.29m and £0.34m loss respectively)

· Cash of £1.9m at period end

 

Strategic initiatives progressing well:

 

· Sale of Byotrol24 in the Americas for gross cash of $1.4m over two years, plus three years of ongoing royalty and potentially significant extra payments to be made to Byotrol contingent on the purchaser's future revenues.

· Solvay continues with its global launch of Actizone 24 hours surface sanitiser and has now received US EPA approval for long-lasting germ kill claims. This is a highly significant step and opens up global supply opportunities for Solvay, from which Byotrol will benefit through its ongoing commission arrangements

· Nearing completion of the academic programme into the mode of action behind brown seaweed's potency as an antiviral technology. The potential for this technology continues to be exciting for the Group.

 

During the year we have been making substantial investment in the team, including:

 

· new leadership of the Professional sales, marketing and business development functions, with two key hires, both with considerable experience in our core markets

· imminent appointment for the first time of a full-time CFO to the Board.

 

 

Outlook

 

Whilst this pandemic is far from over, we find ourselves in a much better position than we were in late 2019.  We have an increasingly integrated, profitable, IP-rich and cash generative business in a much expanded market with enhanced annualised growth.  Accordingly, the Board remains highly confident in medium and long-term growth and, with the benefit of a stronger balance sheet and contractual cash flows from prior IP sales or licenses, is investing further in the team to deliver it, particularly at leadership level in sales and marketing. 

 

After a challenging H1, particularly in hand hygiene products, sales in October and November have been ahead of the average for H1 and the order book is now building strongly, sitting currently at £850k versus an average of £300k in H1 and approximately £350k pre-Covid. Notably this demand includes a number of sizable orders from new customers in both the UK and overseas.

 

Market demand and gross margin, however, is likely to remain volatile in the short term and is subject to a potential negative impact of full and partial lockdowns on the demand for consumables. This is especially so at the current time with the current uncertainty introduced by the new Omicron variant of Covid.

 

Third party interest in our IP and related commercialisation remains strong, with a number of active client discussions under way.  Such agreements can be profitable, but we cannot say with certainty which agreements will close and when. We anticipate our first material royalty income in the current financial year.

 

Whilst we expect to be both profitable and cash generative in the second half of the year, with these uncertainties it is difficult to predict the quantum at this juncture.  At present we are expecting IP sales to offset the majority of the anticipated shortfall  in profit on product sale, but projecting the timing of IP sales is even more uncertain, so we feel it prudent to now reduce market guidance for the current financial year.  Regardless of the timing of our revenues and IP commercialisations over the next four months we remain very well positioned for future growth and are excited by the significant opportunities ahead of us.

 

 

Investor Presentation

 

David Traynor, CEO, and Nic Hellyer, CFO will provide a live presentation relating to these results via the Investor Meet Company platform on 8th Dec 2021 at 2:30pm GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet BYOTROL PLC via:

https://www.investormeetcompany.com/byotrol-plc/register-investor

Investors who already follow BYOTROL PLC on the Investor Meet Company platform will automatically be invited.

 

John Langlands, non-executive Chairman of Byotrol commented:

 

"The Group remains substantially ahead of the pre-Covid period in sales and profits and we expect that performance to endure. 

 

The team is working hard to consolidate and increase the underlying growth, and also to address the short-term challenges in market conditions. We continue to see multiple opportunities for growth in the medium term and are investing confidently to deliver medium and long-term returns. "

 

 

 

 

 

 

For further information contact:

 

Byotrol Plc

 

David Traynor, Chief Executive

+44 (0)1925 742 000

Nic Hellyer, Chief Financial Officer

 

 

 

finnCap Limited (Nominated Adviser and Broker)

+44 (0)20 7220 0500

Geoff Nash/Kate Bannatyne - Corporate Finance

 

Richard Chambers - ECM

 

 

 

Flagstaff Strategic and Investor Communications

+44 (0)20 7129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon  

 

[email protected]

 

 

 

 

This announcement is released by Byotrol Plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person who arranged for the release of this announcement on behalf of Byotrol Plc was Nic Hellyer, CFO.

 

* Comparative figures for H1 2020 restated for closure of US business

** Adjusted EBITDA is defined as Earnings before Interest, Tax, Depreciation and Amortisation and exceptional items, share-based payments, non-trading items such as profit or loss on disposal of assets, plus revenue recognised as interest under IFRS 15

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, go to byotrol.co.uk

 

 

 

Chief Executive's report and financial review

 

The first six months of this financial year have followed the pattern expected by management since last year end, with improvement in all financial indicators compared to pre-Covid, but below the extraordinary results during the peak of the pandemic, and indeed a little below management expectations, particularly in product sales and especially in hand hygiene products.

 

Most market participants have been projecting sales growth in infection control at around 10% across the recent cycle (compared to the 5% normally quoted pre-Covid), which we have exceeded in our own results compared to the first half of our 2020 financial year, and low double digit earnings growth, which we have also exceeded substantially.

 

In line with our strategy, we continued to make progress on the IP side of our business. Larger customers look to us to provide them with future-proofed technologies with the correct regulatory support via licenses or outright sales. This is very solid business once secured, building a long-term cash flow stream, but it is also lumpy revenue-wise and can lead to volatile profitability. Pre pandemic we invested into increasing product sales via the acquisition of Medimark,  but Covid has had the perverse effect of making that side of the business volatile too, at least as the current market conditions persist.

 

That said, we remain very confident in our positioning and in market recovery and have used the extra resources created during the previous financial year to invest in the business:

 

· in the team, especially in sales, marketing and business development. We have invested in new, market-proven leadership in 4 of the 6 operating board positions, including

2 senior sales and marketing professionals with prior national leadership positions at Diversey and Gojo, and at Zoono respectively

a new, full-time CFO;

· in R&D, we have restructured our technical team to concentrate on innovation rather than testing, to take advantage of the myriad of new opportunities available to us, particularly in the fields of virology and sustainable and natural antimicrobial technologies; and

· in systems, especially in integrating the management, HR and supply chain systems of the Group

 

Many of these incremental costs have been offset through a restructuring in the period, which we estimate will result in an exceptional charge of c. £0.2m. Net of this, the investment will result in an increase of c.10% in annualised full year cash costs, which will start paying back in mid/late calendar 2022 as the resulting operational efficiencies feed through.

 

The new team is now working on a more focussed strategy, where we can get the best return for our sales and marketing spend. Byotrol has traditionally (and by necessity given its historical resource constraints) offered its technologies into many different market segments with many different commercials, sold on the basis of its outstanding product performance. This has kept the business growing satisfactorily, but we must now become masters in fewer, discrete segments, talking to clients knowledgably about their businesses and solving their problems where we can. This is a natural and correct evolution of the business and will not result in withdrawing from any current activities, but it will likely mean a shift in how we position ourselves publicly. It should also allow us to deliver a higher net margin as we develop a much more targeted and client focused approach.

 

Results by segment

 

Professional

 

H1 revenues decreased to £2.61m from £5.66m, including £0.75m of royalty and licensing revenue compared to £0.59m in the comparable period. Gross profit on product sales (excluding license revenue) decreased to £0.70m from £1.86m.

 

As reported in September the first half of the year has been a challenge for product sales due to unexpectedly extended lockdowns and office closures and by too much product in our markets chasing too little business consumption. Brexit has not helped either, increasing the amount of administration required to sell our product into the EU and the UK government decision to move away from much of the EU regulatory regime on chemicals. We are now, for instance, increasingly having to re-do regulatory approvals for the UK, based on a new, slightly different to expectations, regime. The good news is that supply chains seem to have stabilised now, and we are now finally starting to reap some benefits from combining the supply chain effort of Byotrol and Medimark.

 

Product mix remained broadly consistent with previous comparable periods, although hand hygiene sales have been some way behind expectations due to overstocking and heavy price discounting by alcohol-based hand sanitiser producers. Of the Professional segments, facilities management and environmental (laboratory supplies) has been much weaker than expected, but human and animal health has been steady, with the latter picking up rapidly as veterinary practices re-open.

 

Consumer

 

H1 revenues decreased to £0.56m from £0.98m, all of which were product sales. Gross profit on products decreased consequently to £0.20m from £0.45m.

 

Given the recent history of the Group, we remain substantially underinvested in consumer product sales and are now taking steps to address this, particularly as we see increasing sales of our anti-viral alcohol-free hand sanitiser sales into Boots. Recent new hires into the Byotrol leadership team should help here.

 

Intellectual Property Sales and Licensing

 

We continue to make progress in monetizing our IP. Of the current activities in place, the three most notable progressions are:

 

· Solvay has now launched Actizone globally, the long-lasting antimicrobial surface sanitiser that Byotrol co-developed and that will pay Byotrol an ongoing commission on all Solvay sales. We are aware of two global company clients of Solvay and two regional companies already launching 24 hour germ kill products into consumer and business markets and are still expecting to report our first sales-based income from this relationship in FY22. Very excitingly, we understand that Solvay has now achieved US EPA approval for long lasting germ kill sanitisers, thus opening up the important US domestic market; we anticipate sizeable demand from global customers seeking global supply chains.

 

· On 30 September we agreed to convert the existing US license agreement on Byotrol24 with Integrated Resources Inc (IRI) into a sale of the formulation in the Americas to IRI, with payments over 2 years. The agreement secured cash payments to Byotrol amounting to US$1.4m in total, with a residual royalty to Byotrol being paid over 3 years, which will ratchet-up further in the event of IRI re-selling the formulation within two years. Simultaneous with this sale, Byotrol entered into a preliminary three-way agreement with IRI and a significant US distribution company ("USCo") to register with EPA and then sell the Formulation into US Professional markets. Should formal registration be achieved, sales by IRI to USCo will accrue further additional royalties to Byotrol.

 

· Our development programme looking into the anti-viral properties of brown seaweed is now confirming and formalising the extraordinary anti-viral properties seen in preliminary in-house testing. We are also now coming to a data-supported conclusion on the mode of action underlying the performance - which we believe will add value to the technology platform. The commercialization effort on seaweed has now commenced.

 

Balance sheet

 

Our balance sheet continues to be strong, with cash at the period end of £1.9m and a healthy balance of receivables from IP sales and licenses providing regular short and medium term cash flows. Our stock position, which was at a high point at the 2021 year end of £1.1m, has now reduced to a more normal £0.7m. Additions to capitalised development costs in the period reflect the Group's usual investment in regulatory and other IP as well as largely one-off expenditure on the Group's patent portfolio.

 

Outlook

 

As we expected mid-pandemic, sales are now  settling at a significantly higher rate than pre-Covid. This underlying growth has been hidden slightly by unusually high overstocking, especially in hand sanitisers, one-off market factors such as Brexit and the resultant pricing pressures in the first half of the year, but this challenge does now seem to be unwinding and our order book has more than doubled since period end.

 

IP sales and activity remains very strong, and incoming levels of enquiry remain high. 

 

We have been busy investing our resources in an upgraded team, with track records of developing new business streams and growing sales generally and this is leading to significantly higher annualised projected annual cost base compared to pre-Covid, before supporting spend on items such as market research and marketing. This is the right thing to do to maximise shareholder returns over the medium term and we are highly confident that payback will accrue in the new financial year, if not earlier. The long-term outlook for your company remains excellent.

 

 

 

David Traynor

Chief Executive

 

 

 

Group statement of comprehensive income

 

 

6 months to

30 September 2021

6 months to

30 September 2020

Year to

31 March

2021

 

Note

£'000

£'000

£'000

 

 

(unaudited)

(unaudited, restated)

(audited)

Revenue

2

3,173

6,657

11,214

Cost of sales

 

(1,517)

(3,746)

(6,359)

 

 

_______

_______

_______

Gross profit

 

1,656

2,911

4,855

 

 

 

 

 

Adjusted administrative expenses

 

(1,633)

(1,747)

(3,486)

 

 

_______

_______

_______

Adjusted operating profit

 

23

1,164

1,369

Amortisation of acquisition-related intangibles

 

(121)

(121)

(243)

Share-based payments

 

(64)

(10)

(111)

 

 

_______

_______

_______

Operating profit

 

(162)

1,033

1,015

 

 

 

 

 

Finance income

4

26

27

66

Finance expense

5

(5)

(18)

(44)

 

 

_______

_______

_______

Profit/(loss) before taxation

 

(141)

1,042

1,037

Income tax credit/(expense)

 

23

48

(58)

 

 

_______

_______

_______

Profit/(loss) for the year from continuing operations

 

(118)

1,090

979

 

 

 

 

 

Discontinued operations

 

 

 

 

(Loss) for the period from discontinued operations

 

-

(83)

(98)

 

 

_______

_______

_______

Profit/(loss) for the period

 

(118)

1,007

881

 

 

 

 

 

Items that may be reclassified subsequently to profit or loss:

 

 

 

 

Exchange differences

 

11

(29)

(98)

 

 

_______

_______

_______

Other comprehensive income/(expense), net of tax

 

11

(29)

(98)

 

 

 

 

 

TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD

 

(107)

978

783

 

 

 

 

 

Total comprehensive income for the year arises from:

 

 

 

 

 - continuing operations

 

(107)

1,061

881

 - discontinued operations

 

-

(83)

(98)

 

 

_______

_______

_______

 

 

(107)

978

783

 

 

 

 

 

Earnings per share - from continuing operations

 

 

 

 

Attributable to the owners of Byotrol plc (basic)

6

(0.03)p

0.25p

0.22p

Attributable to the owners of Byotrol plc (diluted)

6

(0.03)p

0.24p

0.22p

 

 

 

 

 

Earnings per share - from discontinued operations

 

 

 

 

Attributable to the owners of Byotrol plc (basic)

 

n/a

(0.02)p

(0.02)p

Attributable to the owners of Byotrol plc (diluted)

 

n/a

(0.02)p

(0.02)p

 

 

 

 

 

 

 

 

 

 

Earnings per share - from profit for the period

 

 

 

 

Attributable to the owners of Byotrol plc (basic)

 

(0.03)p

0.23p

0.20p

Attributable to the owners of Byotrol plc (diluted)

 

(0.03)p

0.22p

0.19p

 

 

 

 

 

 

 

Group statement of financial position

 

 

As at

30 September 2021

As at

30 September 2020

As at

31 March

2021

 

Note

£'000

£'000

£'000

 

 

(unaudited)

(unaudited)

(audited)

Assets

 

 

 

 

Non-current assets

 

 

 

 

Intangible assets

7

3,617

3,625

3,552

Tangible assets

 

80

57

84

Right-of-use assets

8

41

50

30

Deferred tax assets

 

315

431

315

Trade receivables

 

1,292

1,082

1,249

 

 

_______

_______

_______

 

 

5,345

5,245

5,230

 

 

 

 

 

Current assets

 

 

 

 

Inventories

 

733

1,146

1,099

Trade and other receivables

 

1,772

2,073

1,614

Cash and cash equivalents

 

1,902

1,755

1,598

 

 

_______

_______

_______

 

 

4,407

4,974

4,311

 

 

 

 

 

Total assets

 

9,752

10,219

9,541

 

 

 

 

 

Liabilities

 

 

 

 

Non-current liabilities

 

 

 

 

Lease liabilities

9

16

16

4

Deferred tax liabilities

 

325

371

348

 

 

_______

_______

_______

 

 

341

387

352

 

 

 

 

 

Current liabilities

 

 

 

 

Trade and other payables

 

1,027

1,671

1,023

Lease liabilities

9

26

33

26

 

 

_______

_______

_______

 

 

1,053

1,704

1,049

 

 

 

 

 

Total liabilities

 

1,394

2,091

1,401

 

 

 

 

 

NET ASSETS

 

8,358

8,128

8,140

 

 

 

 

 

Issued share capital and reserves

 

 

 

 

Share capital

 

1,133

1,107

1,116

Share premium

 

434

28,493

190

Other reserves

 

739

1,864

728

Retained earnings

 

6,052

(23,336)

6,106

 

 

_______

_______

_______

TOTAL EQUITY

 

8,358

8,128

8,140

 

 

 

 

 

Group statement of cash flows

 

6 months to

30 September 2021

6 months to

30 September 2020

Year to

31 March

2021

 

£'000

£'000

£'000

 

(unaudited)

(unaudited, restated)

(audited)

Cash flows from operating activities

 

 

 

Profit/(loss) for the period

(118)

1,007

881

Adjustments for:

 

 

 

Finance income

(26)

(27)

(66)

Finance costs

5

18

44

Depreciation of tangible non-current assets

16

12

26

Amortisation of intangible non-current assets

190

203

426

Loss on disposal of assets

17

-

107

Income tax recognised in profit or loss

(23)

(48)

58

Share-based payments

64

10

111

Costs relating to Capital Reduction recognised in equity

-

-

(36)

 

_______

_______

_______

Operating cash flows before movements in working capital

125

1,175

1,551

 

 

 

 

(Increase)/decrease in trade and other receivables

(185)

(315)

37

(Increase)/decrease in inventories

366

(860)

(814)

Increase/(decrease) in trade and other payables

29

580

(34)

Cash in/(out)flow from discontinued operations

-

(47)

(211)

 

_______

_______

_______

Cash (used in)/generated from operating activities

335

533

529

Income tax refund received

-

25

25

 

_______

_______

_______

Net cash (used in)/generated from operating activities

335

558

554

 

 

 

 

Cash flows from investing activities

 

 

 

Development of intangible assets

(272)

(138)

(394)

Acquisition of property, plant and equipment

(12)

(14)

(55)

 

_______

_______

_______

Net cash used in investing activities

(284)

(152)

(449)

 

 

 

 

Cash flows from financing activities

 

 

 

Proceeds from issue of ordinary shares, net of issue costs

261

-

205

Movement in invoice discounting facility

-

(296)

-

Repayments of principal on lease liabilities

(14)

(21)

(39)

Finance income

-

-

53

Finance costs

(4)

(18)

(42)

Interest expense on lease liabilities

(1)

(1)

(2)

 

_______

_______

_______

Net cash (used in)/ generated by financing activities

242

(336)

(121)

 

 

 

 

Net (decrease)/increase in cash and cash equivalents

293

70

(16)

Net foreign exchange differences

11

(27)

(98)

Cash and equivalent at beginning of period

1,598

1,712

1,712

 

_______

_______

_______

Cash and cash equivalents at end of period

1,902

1,755

1,598

 

 

 

 

 

 

 

 

 

Group statement of changes in equity

 

Share capital

Share premium

 

Exchange reserve

Merger reserve

Retained profits

 

Total

 

£'000

£'000

£'000

£'000

£'000

 

£'000

Balance at 31 March 2020

1,101

28,423

826

1,065

(24,353)

 

7,062

Profit/(loss) after taxation for the period

-

-

-

-

1,007

 

1,007

Share-based payments

-

-

-

-

10

 

10

Other comprehensive income:

 

 

 

 

 

 

 

Exchange differences

-

-

(27)

-

-

 

(27)

Transactions with owners:

 

 

 

 

 

 

 

Shares issued for cash

6

70

-

-

-

 

76

 

_____

_____

_____

_____

_____

 

_____

Balance at 30 September 2020

1,107

28,493

799

1,065

(23,336)

 

8,128

(Loss) after taxation for the period

-

-

-

-

(126)

 

(126)

Other comprehensive income:

 

 

 

 

 

 

 

Deferred tax on share-based payment transactions

-

-

-

-

15

 

15

Exchange differences

-

-

(71)

-

-

 

(71)

Share-based payments

-

-

-

-

101

 

101

Transactions with owners:

 

 

 

 

 

 

 

Share-based payments

-

-

-

-

-

 

-

Deferred tax on share-based payment transactions

-

-

-

-

-

 

-

Shares issued for cash

9

120

-

-

-

 

129

Transactions with owners - capital reduction:

 

 

 

 

 

 

 

Capitalisation of Merger reserve to B Ordinary Shares

1,065

-

-

(1,065)

-

 

-

Cancellation of B Ordinary Shares

(1,065)

-

-

-

1,065

 

-

Cancellation of Share Premium

-

(28,423)

-

-

28,423

 

-

Costs of Capital Reduction

-

-

-

-

(36)

 

(36)

 

_____

_____

_____

_____

_____

 

_____

Balance at 31 March 2021

1,116

190

728

-

6,106

 

8,140

Profit/(loss) after taxation for the period

-

-

 

-

(118)

 

(118)

Share-based payments

-

-

 

-

64

 

64

Other comprehensive income:

 

 

 

 

 

 

 

Exchange differences

-

-

11

-

-

 

11

Transactions with owners:

 

 

 

 

 

 

 

Shares issued for cash

17

244

 

-

-

 

261

 

_____

_____

_____

_____

_____

 

_____

Balance at 30 September 2021

1,133

434

739

-

6,052

 

8,358

 

 

Notes to the Group financial statements

 

 

1  Basis of preparation

 

The Group has prepared its interim financial statements for the 6 months ended 30 September 2021 (the "interim results") in accordance with the recognition and measurement principles of International Financial Reporting Standards ("IFRS") as adopted by the European Union and also in accordance with the recognition and measurement principles of IFRS issued by the International Accounting Standards Board, but do not include all the disclosures that would otherwise be required. They have been prepared under the historical cost convention as modified to include the revaluation of certain non-current assets. The accounting policies adopted in the interim financial statements are consistent with those adopted in the Group's Annual Report and Financial Statements for the year ended 31 March 2021 and those which will be adopted in the preparation of the annual report for the year ending 31 March 2022.

 

As permitted, the interim results have been prepared in accordance with the AIM Rules of the London Stock Exchange and not in accordance with IAS34 Interim Financial Reporting. They do not constitute full statutory accounts within the meaning of section 434 of the Companies Act 2006 and are unaudited.

 

Certain comparative amounts for the 6 months ended 30 September 2020 in the Group Statement of Comprehensive Income, Group Statement of Cash Flows and related notes have been reclassified or restated to achieve a more appropriate presentation as required by IFRS 5: Non-current assets held for sale and discontinued operations.

 

Going concern

 

The Directors have considered trading and cash flow forecasts prepared for the Group, and based on these are satisfied that the Group will continue to be able to meet its liabilities as they fall due for at least one year from the date of these results. On this basis, they consider it appropriate to have adopted the going concern basis in the preparation of the interim results, which were approved by the Board of Directors on 7 December 2021.

 

Comparative financial information

 

The comparative financial information presented herein for the year ended 31 March 2021 does not constitute full statutory accounts for that period. The statutory accounts for the year ended 31 March 2021 carried an unqualified Auditor's Report, did not draw attention to any matters by way of emphasis and did not contain a statement under Section 498(2) or 498(3) of the Companies Act 2006.

 

 

2  Segmental analysis

 

Revenue and gross profit by segment

 

 

6 months ended 30 September 2021

Continuing

operations

Discontinued operations

Total

 

Professional

Consumer

 

 

 

£'000

£'000

£'000

£'000

Revenue

 

 

 

 

Product sales

1,862

560

-

2,422

Royalty and licensing income

751

-

-

751

 

_______

_______

_______

_______

Total revenue

2,613

560

-

3,173

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

 

Product sales

705

200

-

905

Royalty and licensing income

751

-

-

751

 

_______

_______

_______

_______

Total gross profit

1,456

200

-

1,656

 

 

 

6 months ended 30 September 2020

Continuing

operations

Discontinued operations

Total

 

Professional

Consumer

 

 

 

£'000

£'000

£'000

£'000

Revenue

 

 

 

 

Product sales

5,067

981

16

6,064

Royalty and licensing income

591

18

-

609

 

_______

_______

_______

_______

Total revenue

5,658

999

16

6,673

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

 

Product sales

1,856

446

(15)

2,287

Royalty and licensing income

591

18

-

609

 

_______

_______

_______

_______

Total gross profit

2,447

464

(15)

2,896

 

 

Revenue by geography

 

The Group recognises revenue in three geographical regions based on the location of customers, as follows:

 

6 months ended 30 September 2021

Professional

Consumer

Total

 

£'000

£'000

£'000

United Kingdom

1,650

366

2,016

North America

751

-

751

Rest of World

212

194

406

 

_______

_______

_______

Total revenue

2,613

560

3,173

 

 

6 months ended 30 September 2020

Professional

Consumer

Total

 

£'000

£'000

£'000

United Kingdom

4,542

456

4,998

North America*

445

-

445

Rest of World

671

543

1,214

 

_______

_______

_______

Total revenue

5,658

999

6,657

* this represents revenue other than that arising from discontinued operations

 

Management makes no allocation of costs, assets or liabilities between these segments since all trading activities are operated as a single business unit.

 

License revenue and finance income

 

License contracts (and certain other contracts relating to the sale of IP) typically provide for fixed payments to be made by customers over a given term (typically between three and five years but which may extend longer). Under IFRS 15, in order to reflect the time value of money, such contracts are recognised as the capitalised value of the income stream plus notional interest accruing for the period on the credit deemed to be extended to the customer (on a reducing balance basis). For the 6 months to 30 September 2021 this figure amounts to license revenue of £0.75m and notional interest income of £26,000.

 

 

3  Non-GAAP profit measures and exceptional items

 

Reconciliation of operating profit to adjusted EBITDA (earnings before interest, taxation, depreciation and amortisation):

 

6 months to

30 September 2021

6 months to

30 September 2020

Year to

31 March

2021

 

£'000

£'000

£'000

 

 

 

 

Operating profit/(loss)

(162)

1,033

1,015

Adjusted for:

 

 

 

Amortisation and depreciation

221

215

491

 

_______

_______

_______

EBITDA

59

1,248

1,506

Loss on disposal of assets

17

-

106

Revenue recognised as interest under IFRS 15

26

27

53

Expensed share-based payments

64

10

111

 

_______

_______

_______

Adjusted EBITDA

166

1,285

1,776

 

The criterion for adjusting items in the calculation of adjusted EBITDA is operating income or expenses that are material and either (i) arise from an irregular and significant event or (ii) are such that the income/cost is recognised in a pattern that is unrelated to the resulting operational performance. Materiality is defined as an amount which, to a user, would influence decision-making based on, and understandability of, the financial statements. Adjustment for share-based payment expense is made because, once the cost has been calculated, the Directors cannot influence the share based payment charge incurred in subsequent years, and the value of the share option to the employee differs considerably in value and timing from the actual cash cost to the Group.

 

Exceptional items are treated as exceptional by reason of their size or nature and are excluded from the calculation of adjusted EBITDA (and adjusted earnings per ordinary share) to allow a better understanding of comparable year-on-year trading and thereby an assessment of the underlying trends in the Group's financial performance. These measures also provide consistency with the Group's internal management reporting.

 

Adjusted EPS

 

The calculation of adjusted EPS is shown in Note 6.

 

 

4  Finance income

 

6 months to

30 September 2021

6 months to

30 September 2020

Year to

31 March

2021

 

£'000

£'000

£'000

 

 

 

 

Interest receivable on interest-bearing deposits

-

-

13

Notional interest accruing on contracts with a significant financing component

26

27

53

 

_______

_______

_______

Total finance income

26

27

66

 

 

5  Finance expense

 

6 months to

30 September 2021

6 months to

30 September 2020

Year to

31 March

2021

 

£'000

£'000

£'000

 

 

 

 

Interest and finance charges

4

17

42

Interest on lease liabilities under IFRS 16

1

1

2

 

_______

_______

_______

Total finance expense

5

18

44

 

 

6  Earnings per share

 

The following sets out the earnings and share data used in the basic and diluted earnings per share computations:

 

Denominator for earnings per share ("EPS") calculations

 

Year to 31 March

6 months to

30 September 2021

6 months to

30 September 2020

Year to

31 March

2021

Weighted number of ordinary shares in issue

452,659,277

441,345,756

442,947,561

Effect of dilutive potential ordinary shares

3,342,894

9,665,218

11,338,201

 

_______

_______

_______

 

456,002,170

451,010,974

454,285,762

 

The Group has one category of potentially dilutive ordinary share, being those share options granted to employees where the exercise price (plus the remaining expected charge to profit under IFRS 2 per option) is less than the average price of the Company's ordinary shares during the period. The weighted average number of shares for the calculation of diluted earnings per share is computed using the treasury share method.

 

Numerator for EPS calculations

 

6 months to 30 September 2021

Continuing operations

Discontinued operations

Total

 

£'000

£'000

£'000

Profit/(loss) attributable to ordinary equity holders of the Company (numerator for basic EPS calculation)

(118)

-

(118)

Adjusting items:

 

 

 

 - share-based payments

64

-

64

- amortisation of acquisition-related intangibles

121

-

121

 - deferred tax credit arising from acquisition-related intangibles

(23)

-

(23)

 

_______

_______

_______

Adjusted earnings attributable to owners of the Parent

(numerator for adjusted EPS calculation)

44

-

44

 

 

6 months to 30 September 2020

Continuing operations

Discontinued operations

Total

 

£'000

£'000

£'000

Profit/(loss) attributable to ordinary equity holders of the Company (numerator for basic earnings per share calculation)

1,090

(83)

1,007

Adjusting items:

 

 

 

 - share-based payments

10

-

10

- amortisation of acquisition-related intangibles

121

-

121

 - deferred tax credit arising from acquisition-related intangibles

(23)

-

(23)

 

_______

_______

_______

Adjusted earnings attributable to owners of the Parent

1,198

(83)

1,115

 

 

Year to 31 March 2021

Continuing operations

Discontinued operations

Total

 

£'000

£'000

£'000

Profit/(loss) attributable to ordinary equity holders of the Company (numerator for basic earnings per share calculation)

979

(98)

881

Adjusting items:

 

 

 

 - share-based payments

111

-

111

- amortisation of acquisition-related intangibles

243

-

243

 - deferred tax credit arising from acquisition-related intangibles

(47)

-

(47)

 

_______

_______

_______

Adjusted earnings attributable to owners of the Parent

1,286

(98)

1,188

 

The criteria for inclusion of adjusting items in the calculation of adjusted EPS are the same as those relating to the calculation of adjusted EBITDA as set out in Note 3. Amortisation of acquisition-related intangibles (and the associated tax credit) relates to the amortisation of intangible assets in respect of customer relationships and brands which are recognised on a business combination and are non-cash in nature.

 

EPS - reported

 

6 months to

30 September 2021

6 months to

30 September 2020 *

Year to

31 March

2021 *

 

£'000

£'000

£'000

Reported earnings per share attributable to shareholders

 

 

 

 - basic

(0.03)p

0.25p

0.22p

 - diluted

(0.03)p

0.24p

0.22p

* Continuing operations only

 

EPS - adjusted

 

6 months to

30 September 2021

6 months to

30 September 2020 *

Year to

31 March

2021 *

 

£'000

£'000

£'000

Adjusted earnings per share attributable to shareholders

 

 

 

 - basic

0.01p

0.27p

0.29p

 - diluted

0.01p

0.27p

0.28p

* Continuing operations only

 

 

 

7  Intangible assets

 

Intangible assets comprise capitalised development costs, acquired software, customer relationships and goodwill.

 

Goodwill

Other Intangible Assets

Total

 

£'000

£'000

£'000

Cost

 

 

 

At 1 April 2021

502

4,639

5,141

Additions

-

272

272

(Disposals)

-

(96)

(96)

 

_____

_______

_______

At 30 September 2021

502

4,815

5,317

 

 

 

 

Amortisation or impairment

 

 

 

At 1 April 2021

-

(1,589)

(1,589)

Charge for the period

-

(190)

(190)

Eliminated on disposal

-

79

79

 

_______

_______

_______

At 30 September 2021

-

(1,700)

(1,700)

 

 

 

 

Net carrying amount

 

 

 

At 30 September 2021

502

3,115

3,617

 

 

 

 

At 1 April 2021

502

3,050

3,552

 

 

Other Intangible Assets comprise:

 

Customer Relationships

Brands

Development Costs

Patents and licenses

Total

 

£'000

£'000

£'000

£'000

£'000

Cost

 

 

 

 

 

At 1 April 2021

1,861

567

1,535

676

4,639

Additions

-

-

178

94

272

(Disposals)

-

-

-

(96)

(96)

 

_______

_______

_______

_______

_______

At 30 September 2021

1,861

567

1,713

674

4,815

 

 

 

 

 

 

Amortisation or impairment

 

 

 

 

 

At 1 April 2021

(485)

(148)

(411)

(545)

(1,589)

Charge for the period

(93)

(28)

(53)

(16)

(190)

Eliminated on disposal

-

-

-

79

79

 

_______

_______

_______

_______

_______

At 30 September 2021

(578)

(176)

(464)

(482)

1,700

 

 

 

 

 

 

Net carrying amount

 

 

 

 

 

At 30 September 2021

1,283

391

1,249

192

3,115

 

 

 

 

 

 

At 1 April 2021

1,376

419

1,124

131

3,050

 

 

8  Right-of-use assets

 

Right-of-use assets comprise leases over office buildings and vehicles.

 

Office

buildings

Vehicles

Total

 

£'000

£'000

£'000

Cost

 

 

 

At 1 April 2021

103

47

150

Additions in the period

-

26

26

(Disposals) in the period

-

(47)

(47)

 

_______

_______

_______

At 30 September 2021

103

26

129

 

 

 

 

Depreciation

 

 

 

At 1 April 2021

(75)

(45)

(120)

Charge for the period

(13)

(2)

(15)

Eliminated on disposal

-

47

47

 

_______

_______

_______

At 30 September 2021

(88)

-

(88)

 

 

 

 

Net carrying amount

 

 

 

At 30 September 2021

15

26

41

At 1 April 2021

28

2

30

 

 

9  Lease liabilities

 

Lease liabilities comprise liabilities arising from the committed and expected payments on leases over office buildings and vehicles.

 

Amounts due in more than one year

Office

equipment

Vehicles

Total

 

£'000

£'000

£'000

At 1 April 2021

4

-

4

Liabilities taken on in the period

-

25

25

Transfers from long to short term liabilities

(4)

(9)

(13)

At 30 September 2021

_______

_______

_______

 

-

16

16

 

 

Amounts due in less than one year

Office

equipment

Vehicles

Total

 

£'000

£'000

£'000

At 1 April 2021

24

2

26

Repayments of principal

(12)

(2)

(14)

Liabilities taken on in the period

-

26

26

Transfers from long to short term liabilities

4

(16)

(12)

 

_______

_______

_______

At 30 September 2021

16

10

26

 

 

10  Post balance sheet events

 

There have been no events subsequent to the reporting date which would have a material impact on these interim financial results

 

 

 [END]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR DKOBKDBDBQBK

a d v e r t i s e m e n t